基于生物信息技术预警他汀类药物防治动脉粥样硬化安全风险

doi:10.19803/j.1672-8629.2021.02.18

中国药物警戒 ›› 2021, Vol. 18 ›› Issue (2): 184-189.
DOI: 10.19803/j.1672-8629.2021.02.18

基于生物信息技术预警他汀类药物防治动脉粥样硬化安全风险

邹丽娜¹, 林志健^1,2, 张晓朦^1,2, 张冰^1,2,*, 黄政凯¹

¹北京中医药大学中药学院,北京 100029;
²北京中医药大学中药药物警戒与合理用药研究中心,北京 100029

收稿日期:2020-06-22 修回日期:2021-02-26 出版日期:2021-02-15 发布日期:2021-02-26
通讯作者: ^*张冰,女,教授·博导,主任医师,中药防治代谢性疾病研究,中药药物警戒与合理用药。E-mail：zhangbing6@263.net
作者简介:邹丽娜,女,在读硕士,药物防治代谢性疾病研究,中药药物警戒与合理用药。
基金资助:
国家中医药管理局-国家中医药领军人才支持计划“岐黄学者”项目(10400633210004）

Early Warning of Risks of Statins in Atherosclerosis Therapy Based on Bioinformatics

ZOU Lina¹, LIN Zhijian^1,2, ZHANG Xiaomeng^1,2, ZHANG Bing^1,2,*, HUANG Zhengkai¹

¹School of Chinese Pharmacy, Beijing University of Chinese Medicine, Beijing 100029, China;
²Research Center of Traditional Chinese Medicine Pharmacovigilance and Rational Use, Beijing University of Chinese Medicine, Beijing 100029, China

Received:2020-06-22 Revised:2021-02-26 Online:2021-02-15 Published:2021-02-26

摘要/Abstract

摘要： 目的通过生物信息技术探讨他汀类药物治疗动脉粥样硬化潜在的安全风险。方法采用生物信息技术提取GEO数据库中的基因芯片数据集GSE32547,对他汀类药物干预人脐静脉内皮细胞差异表达基因进行基因本体注释、信号通路分析以及蛋白质互作网络分析,以探讨其用药风险预警。结果生物信息分析结果显示,他汀类药物治疗动脉粥样硬化时会伴随骨骼肌损伤,以及神经化学传导、甲状腺代谢、呼吸系统及生殖异常的安全风险。结论他汀类药物用于动脉粥样硬化防治具有潜在的不良反应,使用时应密切关注患者骨骼肌状况,对于有骨骼肌疾患的患者应进行风险-效益评价。同时要注意神经系统、内分泌系统、呼吸系统及生殖系统等的用药安全风险。

关键词: 他汀类药物, 动脉粥样硬化, 生物信息技术, 风险预警

Abstract: Objective To explore the potential safety risks of statins in the treatment of atherosclerosis based by bioinformatics. Methods The gene chip data GSE32547 in GEO database was retrieved by bioinformation technology. GO annotation, KEGG pathway analysis and protein interaction network analysis were conducted of the genes differentially expressed in HUVECs cells by statins to identify the safety risk of statins in the treatment of atherosclerosis. Results The results showed that the treatment of atherosclerosis with statins could be accompanied by skeletal muscle injuries and abnormalities in neurochemical conduction, thyroid metabolism, the respiratory system and fertility. Conclusion Statins can cause potential adverse reactions when used in the prevention and treatment of atherosclerosis. When statins are used for treating atherosclerosis, the condition of a patient's skeletal muscle deserves attention. When patients with skeletal muscle disease take statins, the risk/benefit to patients should be evaluated. Clinicians should be alert to safety risks to the nervous system, endocrine system, respiratory system and reproductive system.

Key words: statins, atherosclerosis, bioinformatics, risk warning

中图分类号:

R972.6

邹丽娜, 林志健, 张晓朦, 张冰, 黄政凯. 基于生物信息技术预警他汀类药物防治动脉粥样硬化安全风险[J]. 中国药物警戒, 2021, 18(2): 184-189.

ZOU Lina, LIN Zhijian, ZHANG Xiaomeng, ZHANG Bing, HUANG Zhengkai. Early Warning of Risks of Statins in Atherosclerosis Therapy Based on Bioinformatics[J]. Chinese Journal of Pharmacovigilance, 2021, 18(2): 184-189.

参考文献

[1] Jacobson MD, Terry A.NLA task force on statin safety - 2014 update[J]. Journal of Clinical Lipidology, 2014, 8(3): S1-S4.
[2] Statins safety evaluation working group. Expert consensus on statins safety evaluation, 2014[J]. Chinese Journal of Cardiovascular Disease(中华心血管病杂志), 2014, 42(11): 890-894.
[3] Veronese N, Koyanagi A, Stubbs B, et al.Statin use and knee osteoarthritis outcomes: a longitudinal cohort study[J]. Arthritis Care & Research, 2019,71(8): 1052-1058.
[4] Stroes ES, Thompson PD, Corsini A, et al.Statin-associated muscle symptoms:impact on statin therapy-european atherosclerosis society consensus panel statement on assessment, aetiology and management[J]. European Heart Journal, 2015, 36(17): 1012-1022.
[5] Meurer L, Cohen SM.Drug-Induced Liver Injury from Statins[J]. Clinics in Liver Disease, 2020, 24(1): 107-119.
[6] Morris M, Li L.Molecular mechanisms and pathological consequences of endotoxin tolerance and priming[J]. Archivum Immunologiae et Therapiae Experimentalis, 2012, 60(1): 13-18.
[7] Ross R.The pathogenesis of atherosclerosis-an update[J]. The New England Journal of Medicine, 1986, 341(8): 488-500.
[8] Guo YL, Liu S.Inflammatory factors of atherosclerosis: infection and autoimmune diseases[J]. Journal of Practical Medicine(实用医学杂志), 2016,32(10): 1713-1716
[9] Ross Rl.The pathogenesis of atherosclerosis: a perspective for the 1990s[J]. Nature, 1993, 362(6423): 801-809.
[10] Fernandez G, Spatz ES, Jablecki C, et al.Statin myopathy: a common dilemma not reflected in clinical trials.[J]. Cleveland Clinic Journal of Medicine, 2011, 78(6): 393-403.
[11] Atul T, Vinay B, Anita C, et al.Statins and myotoxicity: a therapeutic limitation.[J]. Expert Opinion on Drug Safety, 2006, 5(5): 651.
[12] Duewell P, Kono H, Rayner KJ, et al.NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals[J]. Nature, 2010, 466(7306): 652-652.
[13] Yu L, Shanqin X, Bingbing J, et al.Activation of sterol regulatory element binding protein and NLRP3 inflammasome in atherosclerotic lesion development in Diabetic Pigs[J]. Plos One, 2013, 8(6): e67532.
[14] Lin J, Shou X, Mao X, et al.Oxidized low density lipoprotein induced caspase-1 mediated pyroptotic cell death in macrophages: implication in lesion instability[J]. Plos One, 2013, 8(4): e62148.
[15] Giles. JT.Cardiovascular disease in rheumatoid arthritis: current perspectives on assessing and mitigating risk in clinical practice[J]. Best Practice & Research Clinical Rheumatology, 2015, 29(4-5): 597-613.
[16] Montocuoco F, Mach F.New evidences for c-reactive protein (CRP) deposits in the arterial intima as a cardiovascular risk factor[J]. Clinical Interventions in Aging, 2008, 3(2): 341-349.
[17] Shiotsugu S, Okinaga T, Habu M, et al.The biological effects of interleukin-17A on adhesion molecules expression and foam cell formation in Atherosclerotic Lesions.[J]. Journal of Interferon & Cytokine Research, 2019, 39(11): 694-702.
[18] Mao Y, Liu XQ, Wang HM, et al.ICAM-1 and VCAM-1 promote angiogenesis in atherosclerotic plaques of rabbits[J]. Chinese Journal of Arteriosclerosis(中国动脉硬化杂志), 2014, 22(3): 217-222.
[19] Zhang X, Zeng Y, Qu Q, et al.PD-L1 induced by IFN-γ from tumor-associated macrophages via the JAK/STAT3 and PI3K/AKT signaling pathways promoted progression of lung cancer[J]. International Journal of Clinical Oncology, 2017, 22(6): 1026-1033.
[20] Shu L, Zhong P, Hao YQ, et al.Rosuvastatin alleviates carotid atherosclerosis in mice by inhibiting the activity of PI3K / Akt signaling pathway[J]. Anatomical Research(解剖学研究), 2020, 42(1): 44-49.
[21] Li LJ, Wen ZY, He ZH, et al.Effects of polydatin on atherosclerosis in ApoE ~ (- / -) mice via PI3K / Akt / FoxO1 signaling pathway[J]. Chinese Journal of Preventive Medicine(解放军预防医学杂志), 2020, 38(1): 29-32.
[22] Hansson GK, Jonasson L, Holm J, et al.ClassⅡMHCantigen expression in the atherosclerotic plaque: smooth muscle cells express HLA-DR, HLA-DQ and the invariant gamma chain[J].Clinical & Exprimental Immunology, 1986, 64(2): 261-268.
[23] Takayuki K, Kevin T, Alessandro S, et al.Vaccination to modulate atherosclerosis[J]. Autoimmunity, 2015, 48(3): 152-160.
[24] Guo ML, Xuan J Tian L, et al. Comprehensive multi-omics analysis identified core molecular processes in esophageal cancer and revealed GNGT2 as a potential prognostic marker[J].World Journal of Gastroenterology, 2019, 25(48): 6890-6901.
[25] Zhou Z, Subramanian P, Sevilmis G, et al.Lipoprotein-derived lysophosphatidic acid promotes atherosclerosis by releasing CXCL1 from the endothelium.[J]. Cell Metabolism, 2011, 13(5): 592-600.
[26] Polonskaya YV, Kashtanova EV, Murashov IS, et al.Associations of osteocalcin, osteoprotegerin, and calcitonin with inflammation biomarkers in atherosclerotic plaques of coronary arteries[J]. Bulletin of Experimental Biology & Medicine, 2017, 162(6): 726-729.
[27] Nakabayashi K, Matsumi H, Bhalla A, et al.Thyrostimulin, a heterodimer of two new human glycoprotein hormone subunits, activates the thyroid-stimulating hormone receptor[J]. Journal of Clinical Investigation, 2002, 109(11): 1445-1452.
[28] Costagliola S.Tyrosine sulfation is required for agonist recognition by glycoprotein hormone receptors[J]. Embo Journal, 2014, 21(4): 504-513.
[29] Tahira F, Farooqui AA.Trace amines and neurological disorders[M]. Elsevier Inc: Academic Press, 2017.
[30] Akira H, Jun K, Satoshi K.Experimental study on the role of prostaglandin D2 in the pathogenesis of bronchial asthma[J]. The Japanese Respiratory Society, 1992, 30(6): 1091.
[31] Yoshihiro T, Ichiro K, Yasue K, et al.Lipocalin-type prostaglandin D synthase in human male reproductive organs and seminal plasma1[J]. Biology of Reproduction, 1998, 58(2): 600-607.
[32] Ulrich-lai YM, Figueire do HF, Ostrander MM, et al. Chronic stress induces adrenal Hyperplasia andhypertrophy in a subregion-specific manner[J]. American Journal of Physiology Endocrinology & Metabolism, 2006, 291(5): E965.
[33] Hauser J, Leszczynska A, Samochowiec J, et al.Association analysis of the insertion/deletionpolymorphism in serotonin transportergene in patientswith affective disorder[J]. European Psychiatry the Journal of the Association of European Psychiatrists, 2003, 18(3):129-132.
[34] Haghighi M, Khodakarami S, Jahangard L, et al.In a randomized, double-blind clinical trial, adjuvant atorvastatin improved symptoms of depression and blood lipid values in patients suffering from severe major depressive disorder[J]. Journal of Psychiatric Research, 2014, 58: 109-114.
[35] Parsaik AK, Singh B, Hassan M, et al.Statins use and risk of depression: a systematic review and meta-analysis[J]. Journal of Affective Disorders, 2014, 160: 62-67.
[36] Afroze S, Meng F, Jensen K, et al.The physiological roles of secretin and its receptor.[J] Annals of Translational Medicine, 2013,1(3): 29.
[37] Chow BKC.Molecular cloning and functional characterization of a human secretin receptor[J]. Biochemical & Biophysical Research Communications, 1995, 212(1): 204-211.

基于生物信息技术预警他汀类药物防治动脉粥样硬化安全风险

Early Warning of Risks of Statins in Atherosclerosis Therapy Based on Bioinformatics

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 12

编辑推荐

Metrics

[1]	邵晨, 张青霞, 闫素英, 王育琴. 他汀类药物1028例用药错误报告分析及防范策略[J]. 中国药物警戒, 2022, 19(6): 645-648.
[2]	张晓朦, 吕锦涛, 张冰, 林志健, 刘荣雪. 蟾酥类注射液治疗肝癌的风险评价与预警研究[J]. 中国药物警戒, 2022, 19(5): 469-474.
[3]	姜睿琦, 梅升辉, 赵志刚. 性别差异对循环系统常见慢性疾病药物治疗的影响研究进展[J]. 中国药物警戒, 2022, 19(10): 1145-1148.
[4]	王雨, 林志健, 姜卓希, 杨婷, 王笑, 张冰. 生物信息技术预警乌头类中药抗乳腺癌用药风险[J]. 中国药物警戒, 2021, 18(7): 655-662.
[5]	陈捷, 吴磊, 吴杨霞, 潘敉, 段自皞, 朱枝祥. 高脂血症患者他汀类用药依从性影响因素探讨及风险预测[J]. 中国药物警戒, 2021, 18(11): 1070-1074.
[6]	毛秋月, 林志健, 王雨, 张冰, 萨翼. 生物信息学技术预警番泻叶用于乳腺癌便秘患者的用药风险[J]. 中国药物警戒, 2021, 18(1): 30-37.
[7]	蓝晓红, 周永刚, 臧菊香, 吴冬妮, 李祥, 许锐, 陈曙东, 于浩, 张烨. 临床药师主导的社区药学服务对老年患者他汀类药物治疗服务系统构建与评价的影响[J]. 中国药物警戒, 2020, 17(9): 594-599.
[8]	张荔, 侯立静, 孙付军, 李贵海, 黄德红, 盛国梁. 温阳通脉颗粒对人脐静脉内皮细胞氧化损伤的保护作用[J]. 中国药物警戒, 2020, 17(12): 856-860.
[9]	张荔, 黄德红, 孙付军, 李贵海. 淫羊藿苷对H₂O₂诱导HUVECs细胞氧化损伤的保护作用[J]. 中国药物警戒, 2019, 16(10): 581-587.
[10]	高千秋, 张浩嘉. 302例他汀类药物相关肌肉系统损害的文献分析[J]. 中国药物警戒, 2018, 15(8): 476-480.
[11]	殷小杰, 马晓静, 王岚, 贡磊磊, 李丽, 肖永庆, 梁日欣. 三黄泻心汤“炮制配伍”活血化瘀优势方抗大鼠动脉粥样硬化作用的研究[J]. 中国药物警戒, 2017, 14(9): 518-522.
[12]	孙怡园,邓剑雄,杨悦. 改进的加权关联规则算法在识别企业生产风险的应用[J]. 中国药物警戒, 2017, 14(6): 346-349.